IMUGENE LIMITED (IMU)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IMU

IMU - IMUGENE LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.15
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.115

07 May
2026

0.010

OPEN

$0.11

9.52%

HIGH

$0.12

1,347,908

LOW

$0.11

TARGET
$0.25

-0.57 change from previous day

 117.4% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGN . ARX . ATH . AVH . BIO . BOT . COV . CSL . CUV . DXB . GSS . HXL . IDT . ILA . IMM . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
IMU: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx - 31.6 - 14.4 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 N/A

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-31.6
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxxxxxxxx20.5
Net Operating Cash Flow xxxxxxxxxxxxxxx-75.7 M
Net Profit Margin xxxxxxxxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-84.54 %
Return on Invested Capital xxxxxxxxxxxxxxx-82.78 %
Return on Assets xxxxxxxxxxxxxxx-58.75 %
Return on Equity xxxxxxxxxxxxxxx-84.54 %
Return on Total Capital xxxxxxxxxxxxxxx-84.86 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-83.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx8 M
Long Term Debt xxxxxxxxxxxxxxx3 M
Total Debt xxxxxxxxxxxxxxx11 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx22 M
Price To Book Value xxxxxxxxxxxxxxx2.16

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx14.5 M
Capex % of Sales xxxxxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxxxxx3 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx71 M
Research & Development xxxxxxxxxxxxxxx47 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

08/05/2026

1

Buy

$0.25

117.39%

Imugene has continued to make steady progress with its Phase 1b Azer-cel trial, Bell Potter reports, most notably in the indication for patients with Diffuse Large B Cell Lymphoma (DLBCL).

The recent type C meeting with the FDA has illuminated the pathway to an initial approval for Azer-cel in this indication with the added advantage of accelerated approval based on overall response rate and durability, with full approval based on progression free survival only.

Approval for this indication is likely to require the resources of a larger partner, Bell Potter suggests.

Bell Potter retains Speculative Buy, cutting its target to 25c from 82c due to dilution from a recent capital raise.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -14.40 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -8.70 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

IMU STOCK CHART

FNArena News on IMU

1
The Biotech ‘Industrialisation’

Apr 20 2026 - Small Caps
2
Next Week At A Glance 16-20 Mar 2026

Mar 13 2026 - Weekly Reports
3
Rudi’s View: Mate, Where Have The Profits Gone?

Nov 06 2024 - Rudi's View
4
May In Review: Inflation Spoils The ASX Party

Jun 05 2024 - Australia
5
Dr Boreham’s Crucible: Imugene

Dec 11 2023 - Small Caps

Latest Pharmaceuticals & Biotech/Lifesciences News

1
The Biotech ‘Industrialisation’

Apr 20 2026 - Small Caps
2
Telix’ Double-Product Strategy On A Roll

Apr 10 2026 - Australia
3
Focus On Telix’ Guidance Post Annus Horribilis

Jan 22 2026 - Australia
4
Anti-Vaxxers & China Cloud CSL’s Future

Oct 31 2025 - Australia
5
Rudi Interviewed: Diary Of A Successful Investor

Oct 20 2025 - Rudi's View
6
Is CSL Starting Its Price Recovery?

Sep 30 2025 - Technicals
7
Undervalued ASX Gems In Precision Medicine

Sep 23 2025 - Small Caps
8
Earnings Result Leaves CSL Bloodied

Aug 21 2025 - Australia
9
Renewed Momentum For CSL Shares

Jul 22 2025 - Technicals
10
Treasure Chest: CSL Not A One-Trick Pony

Jul 14 2025 - Treasure Chest